Guangzhou Innogen Pharmaceutl Grp Co Ltd
2591.HKHKSEHealthcareBiotechnology
Latest quote
HK$4.06
−HK$0.015 · -0.37%
Aug 24, 3:59 PM HKT
2591.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteGuangzhou Innogen Pharmaceutical Group Co Ltd operates as a China-based investment holding firm with a core mission to research, develop, and bring to market medicinal products. The company specializes in producing innovative, human-compatible, and extended-duration GLP-1 receptor agonists, specifically targeting the treatment of diabetes and other metabolic conditions.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Qinghua Wang
- Listed since
- Aug 15, 2025
- Employees
- 193
Market position
- Volume
- 5.12M
- 1.15× average
- Average volume
- 4.43M
- Average daily volume
- Market cap
- 1.86B HKD
- Beta
- 1.28
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -4.53×
- P/B (TTM)
- 1.46×
- P/S (TTM)
- 12.33×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 89.01%
- Operating margin
- -254.47%
- Net margin
- -259.64%
Financial health
- Debt / equity
- 0.16×
ETFs holding 2591.HK
Funds reporting this stock among their holdings, ordered by reported position size.
ETFMarket valueWeightAUMExpense ratioPrice / 1D
Continue in GoAI
Research 2591.HKresearch.disclaimer